Avoro Capital Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.8M | Sell |
3,725,000
-920,548
| -20% | -$4.15M | 0.29% | 27 |
|
|
2025
Q1 | $21.6M | Buy |
4,645,548
+300,548
| +7% | +$1.39M | 0.34% | 30 |
|
|
2024
Q4 | $30.2M | Sell |
4,345,000
-1,445,236
| -25% | -$10M | 0.43% | 30 |
|
|
2024
Q3 | $30.7M | Buy |
5,790,236
+1,255,236
| +28% | +$6.65M | 0.45% | 30 |
|
|
2024
Q2 | $17M | Hold |
4,535,000
| – | – | 0.23% | 36 |
|
|
2024
Q1 | $32M | Hold |
4,535,000
| – | – | 0.37% | 40 |
|
|
2023
Q4 | $25.6M | Hold |
4,535,000
| – | – | 0.35% | 34 |
|
|
2023
Q3 | $21.7M | Hold |
4,535,000
| – | – | 0.34% | 31 |
|
|
2023
Q2 | $31.1M | Buy |
4,535,000
+210,000
| +5% | +$1.44M | 0.42% | 29 |
|
|
2023
Q1 | $33.7M | Hold |
4,325,000
| – | – | 0.5% | 26 |
|
|
2022
Q4 | $32.9M | Buy |
4,325,000
+961,667
| +29% | +$7.32M | 0.49% | 29 |
|
|
2022
Q3 | $27.5M | Buy |
3,363,333
+51,797
| +2% | +$423K | 0.51% | 28 |
|
|
2022
Q2 | $32M | Buy |
3,311,536
+102
| +0% | +$986 | 0.63% | 25 |
|
|
2022
Q1 | $46.4M | Hold |
3,311,434
| – | – | 0.85% | 20 |
|
|
2021
Q4 | $67.6M | Hold |
3,311,434
| – | – | 1.15% | 17 |
|
|
2021
Q3 | $61M | Hold |
3,311,434
| – | – | 0.96% | 21 |
|
|
2021
Q2 | $62.2M | Buy |
+3,311,434
| New | +$62.2M | 1.08% | 21 |
|